Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21568323 | 0.86 | DYRK1A (0.65) | SMN1; SMN2MEN1KMT2AHPGDDYRK1A | |
| SCHEMBL21568259 | 0.86 | LMNA (0.66) | SMN1; SMN2MEN1KMT2ADYRK1AHSD17B10 | |
| SCHEMBL23256883 | 0.85 | DYRK1A (0.66) | SMN1; SMN2MEN1KMT2ADYRK1AHSD17B10 | |
| SCHEMBL23256551 | 0.85 | DYRK1A (0.60) | SMN1; SMN2MEN1KMT2AHPGDDYRK1A | |
| SCHEMBL21568130 | 0.84 | DYRK1A (0.65) | SMN1; SMN2MEN1KMT2AHPGDDYRK1A | |
| SCHEMBL21568073 | 0.84 | DYRK1A (0.62) | SMN1; SMN2MEN1KMT2ADYRK1AHSD17B10 | |
| SCHEMBL23256895 | 0.84 | DYRK1A (0.68) | SMN1; SMN2MEN1KMT2ADYRK1AMAPT | |
| SCHEMBL21568123 | 0.84 | DYRK1A (0.65) | SMN1; SMN2MEN1KMT2ADYRK1AHSD17B10 | |
| SCHEMBL21568257 | 0.84 | KDM4E (0.61) | MEN1KMT2ADYRK1AHSD17B10MAPT | |
| SCHEMBL23256870 | 0.84 | DYRK1A (0.70) | SMN1; SMN2MEN1KMT2AHPGDDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | SMN1; SMN2 3105/4885MEN1 977/4885KMT2A 623/4885 |
| US-20210115064-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | VHL, TP53, NUDT1 | SMN1; SMN2 3703/4885MEN1 1079/4885KMT2A 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.